Cross-cutting research priorities

Published on 21 July 2023

Two flagship programmes constitute the pillars of our cross-cutting research priorities:

  • research into vaccines (HIV, HCV, TB, priority emerging pathogens) marked by a fluid and effective continuum from basic research to clinical evidence and the advanced pre-industrial and industrial development phases.
  • research into cures (HIV, HBV, HDV), with our commitment to ensuring full synergy between our various Cure programmes.

The other cross-cutting research priorities concern the triple elimination of the mother-to-child transmission of HIV, HBV and syphilis (a WHO initiative), mathematical modelling and reflection regarding a sexual health research agenda.

Scientific facilitation, driven by our Coordinated Action groups, has the major role of refining and growing the scientific priorities identified.

Values and guiding principles

To succeed in its missions, our agency remains rooted in the values that have always guided it, namely scientific excellence, multidisciplinarity, the systematic involvement of civil society and affected populations (including community-based participatory research) and a global perspective that goes beyond national borders. We are also committed to openness and transparency, and strongly support data sharing.

To implement our ambitious research programme, we endeavour to strengthen research capabilities in France and in our partner countries through the development and consolidation of infrastructures and networks. We are also developing a dual approach complementary to an ‘upwards’ and ‘downwards’ process to attract and fund research, the first involving researchers proposing research programmes for evaluation by us and the second that we set priorities to which researchers can respond.

Finally, we are committed to advocating for the simplification of regulatory requirements at national and European level, to improve the flexibility and effectiveness of research in times of crisis, particularly in the area of emerging infectious diseases.